MedPath
NMPA Approval

Fluticasone Furoate and Vilanterol Trifenatate Powder for Inhalation (Ⅱ)

国药准字HJ20180044

June 7, 2023

H20180044

Drug Information

糠酸氟替卡松维兰特罗吸入粉雾剂(Ⅱ)

万瑞舒

吸入制剂

每泡含糠酸氟替卡松100μg与三苯乙酸维兰特罗25μg(按C₂₄H₃₃Cl₂NO₅计),递送剂量为糠酸氟替卡松92μg与三苯乙酸维兰特罗22μg(按C₂₄H₃₃Cl₂NO₅计)

化学药品

June 7, 2023

June 6, 2028

Company Information

Applicant Company

12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland

Manufacturing Company

glaxo operations(uk)ltd. (trading as glaxo wellcome operations)

Priory Street, Ware, Hertfordshire, SG12 0DJ, United Kingdom

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

糠酸氟替卡松维兰特罗吸入粉雾剂(Ⅱ) - NMPA 批准文号 | MedPath